BCHE and Alzheimer disease: In the present study, we sought to determine if treatment during AIE (i.e., P25–P54) with the cholinesterase inhibitor galantamine, which is approved for the treatment of AD (Lilienfeld, 2002; Haake et al., 2020), would prevent the loss of BFCN markers in the adult (i.e., P70) basal forebrain.